PsychedelicNewsBreaks Archive - Page 8 of 65

TuesdayMar 14, 2023 12:45 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that it has renewed the service agreement with ShareIntel-Shareholder Intelligence Services LLC (www.ShareIntel.com). Under the agreement, ShareIntel will assist in ongoing investigations related to suspected naked short selling of FSD Pharma’s common stock. “Our shareholders can rest assured that we have heard their concerns. We are acting appropriately with all tools at our disposal to identify any nefarious perpetrators. We, as fervent advocates for naked short…

WednesdayMar 08, 2023 12:16 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, at 12:40 p.m. ET. Interested parties should visit https://ibn.fm/4Qlqa to register for and access the webcast. The archived version will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/x9P1S About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working with…

MondayMar 06, 2023 1:18 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced debt settlements. According to the announcement, the company announced settlements for debt owed to some arms-length creditors, service providers and debtors of the company. The company noted that the agreements call for debt to be converted into common shares in the capital of the company. The debt settlements should eliminate an estimated $752,160 of liabilities; some 1,299,998 shares were issued as a result…

FridayMar 03, 2023 1:17 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15 formulation by the U.S. Patent and Trademark Office (“USPTO”). “The patent, titled ‘Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females’, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions. SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD… SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors.…

FridayMar 03, 2023 10:24 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds: Innovations in Consciousness, Psychedelics & Mental Health.” The SXSW event is slated for March 10–19, 2023, and will be held in Austin, Texas. The panel that Drysdale and Chopra are participating on is scheduled for March 12 at 11:30 a.m. CT. According to the announcement, other panel members include Cristie Strongman MA, EdM, a psychotherapist at the Multidisciplinary Association for Psychedelic Studies (MAPS),…

WednesdayMar 01, 2023 12:39 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) News Discussed in Latest InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a recent InvestmentPitch Media video release. The video focused on FSD Pharma’s recent announcement that entrepreneur Kevin Harrington was joining its advisory board. According to the announcement, Harrington, the inventor of the modern infomercial format and one of the original “sharks” on the hit ABC show “Shark Tank,” will help expand the reach of the company and its brands. Company officials noted that, with Harrington’s…

TuesdayFeb 28, 2023 11:36 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that iconic entrepreneur Kevin Harrington has joined its advisory board. Harrington is world renowned as the inventor of the informercial, pioneer of the “As Seen on TV” brand, and one of the original “sharks” on the hit ABC show “Shark Tank.” He has launched more than 20 businesses as part of a career that has introduced 1,000+ products generating over $6 billion in global sales. “Kevin…

TuesdayFeb 28, 2023 11:29 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive disorder (“MDD”), and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of generalized anxiety disorder (“GAD”). According to the announcement, interim data from the CYB003 phase 1/2a study exhibited rapid and short-acting effects; strong psychedelic effects at low doses; and a positive safety and tolerability profile. The company anticipates having top-line efficacy data by late Q3 2023. In addition, initial…

ThursdayFeb 23, 2023 10:04 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and long-term milestones. A part of that plan was the release of an estimated 15% of Cybin’s workforce, including those in roles that were identified as not a clinical priority or not directly involved with any clinical trial initiatives. This move alone is expected to generate cost savings by reducing operating expenses. The announcement noted that with the anticipated cost savings from the overall streamlining…

TuesdayFeb 21, 2023 11:18 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participation in the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2023 Forum taking place from Feb. 23-25 in San Diego, California, at the Marriott Marquis San Diego Marina. Founded in 1995, ACTRIMS is comprised exclusively of multiple sclerosis (“MS”) researchers and clinicians. “ACTRIMS provides us with an opportunity to interact with an esteemed community of leaders pushing the boundaries…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks